Frederickson E D, Wilcox C S, Bucci M, Loon N R, Peterson J C, Brown N L, Thompson R D, Smith T B, Wingo C S
Department of Medicine, University of Florida, Gainesville.
Arch Intern Med. 1990 Mar;150(3):569-72.
Renovascular hypertension is potentially curable but of low prevalence. A previous retrospective study has demonstrated the use of a potentiated increase in plasma renin activity after captopril administration as a diagnostic test for renovascular hypertension; this requires two blood samples for plasma renin activity determination and three inclusive criteria for a positive test result. We applied this test prospectively to screen 100 hypertensive patients for renovascular hypertension. We evaluated 29 patients with renovascular hypertension; the remainder were diagnosed as having essential hypertension. In our patient population, a postcaptopril plasma renin activity of 5.7 ng of angiotensin per milliliter per hour (ngAl.mL-1.h-1) or greater had a 100% sensitivity and an 80% specificity for renovascular hypertension. An absolute increase in plasma renin activity with captopril of 4.7 ngAl.mL-1.h-1 or greater had a lower sensitivity of 90% and a specificity of 87%, whereas a fractional increase in plasma renin activity after captopril of 150% or higher had the lowest sensitivity of 69% and a specificity of 86%. A subgroup analysis of 38 patients who were receiving diuretic therapy demonstrated that the test sensitivity was unchanged but the specificity was reduced. In conclusion, a single postcaptopril plasma renin activity value of 5.7 ngAl.mL-1.h-1 or greater is a simplified screening test for renovascular hypertension, with excellent sensitivity and acceptable specificity. This test is well tolerated, inexpensive, and easy to perform.
肾血管性高血压有可能治愈,但发病率较低。此前一项回顾性研究已证明,卡托普利给药后血浆肾素活性的增强升高可作为肾血管性高血压的诊断测试;这需要采集两份血样来测定血浆肾素活性,且阳性测试结果需满足三项纳入标准。我们前瞻性地应用此测试对100例高血压患者进行肾血管性高血压筛查。我们评估了29例肾血管性高血压患者;其余患者被诊断为原发性高血压。在我们的患者群体中,卡托普利给药后血浆肾素活性为每毫升每小时5.7纳克血管紧张素(ngAl.mL-1.h-1)或更高时,对肾血管性高血压的敏感性为100%,特异性为80%。卡托普利使血浆肾素活性的绝对增加值为4.7 ngAl.mL-1.h-1或更高时,敏感性较低,为90%,特异性为87%,而卡托普利给药后血浆肾素活性的分数增加值为150%或更高时,敏感性最低,为69%,特异性为86%。对38例接受利尿剂治疗的患者进行的亚组分析表明,测试敏感性未变,但特异性降低。总之,卡托普利给药后单次血浆肾素活性值为5.7 ngAl.mL-1.h-1或更高是一种用于肾血管性高血压的简化筛查测试,具有出色的敏感性和可接受的特异性。该测试耐受性良好、成本低廉且易于操作。